SU5416 in Treating Patients With AIDS-Related Kaposi's Sarcoma

Completed · Phase 1

Conditions studied: Sarcoma

In brief

RATIONALE: SU5416 may stop the growth of Kaposi's sarcoma by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of SU5416 in treating patients who have AIDS-related Kaposi's sarcoma.

Key facts

Study ID

NCT00003720

Run by

Pfizer

Starts

1998-07-01

Last updated by the study team

2012-08-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• USC/Norris Comprehensive Cancer Center — Los Angeles, California, United States
• Jonsson Comprehensive Cancer Center, UCLA — Los Angeles, California, United States
• St. Francis Hospital — San Francisco, California, United States
• Kaplan Cancer Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.